Effects of IV Chloride Content on Outcomes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02083198 |
Recruitment Status :
Completed
First Posted : March 11, 2014
Last Update Posted : June 21, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
SIRS Balanced Fluids Plasmalyte |
Study Type : | Observational |
Actual Enrollment : | 1558 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | A Comparison of High and Low Chloride Containing IV Fluid Solutions in Patients Undergoing Major Surgery and/or ICU Admission |
Actual Study Start Date : | September 2013 |
Actual Primary Completion Date : | April 1, 2014 |
Actual Study Completion Date : | April 1, 2014 |

Group/Cohort |
---|
High Chloride
Patients receiving .9% sodium choride for resuscitation
|
Low chloride
Patients receiving Plasmalyte for resuscitation
|
- Mortality [ Time Frame: Hospitalization, Expected Length of inpatient stay is approximately 7 days ]Inpatient mortality. Expected Length of inpatient stay is approximately 7 days
- Length of Stay [ Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days ]
- Acute renal failure [ Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days ]
- Infections [ Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days ]
- dysrhythmias [ Time Frame: inpatient hospitalization, Expected Length of inpatient stay is approximately 7 days ]
- Electrolyte disorders [ Time Frame: inpatient hospitalizationExpected Length of inpatient stay is approximately 7 days ]
- readmission [ Time Frame: 30, 60 and 90 day ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Adults meeting SIRS criteria receiving at least 500 mL of fluid replacement on day of SIRS.
Exclusion Criteria:
- Receipt of starches or other colloids

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02083198
United States, Illinois | |
Baxter Healthcare | |
Deerfield, Illinois, United States, 60015 |
Responsible Party: | Baxter Healthcare Corporation |
ClinicalTrials.gov Identifier: | NCT02083198 |
Other Study ID Numbers: |
Bax-BSP-HiLoCl |
First Posted: | March 11, 2014 Key Record Dates |
Last Update Posted: | June 21, 2017 |
Last Verified: | June 2017 |
hyperchloremic acidosis balanced fluids plasmalyte |